Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis

Table 2

Leave-one-out sensitivity analysis for the effects of newer antidiabetics on endothelial function.

Study excluded	MD (95% CI)	value	Heterogeneity (^2)
DPP-4 inhibitors
Ayaori et al. [31]	1.253 (0.242 to 2.265)		87.7%,
Baltzis et al. [32]	0.866 (-0.205 to 1.936)		88.6%,
Dell’Oro et al. [34]	0.658 (-0.365 to 1.682)		87.8%,
Ida et al. [52]	0.897 (-0.151 to 1.945)		88.5%,
Nakamura et al. [24]	0.858 (-0.226 to 1.943)		88.6%,
Kim et al. [37]	0.962 (-0.066 to 1.990)		88.3%,
Kitao et al. [38]	0.948 (-0.115 to 2.011)		87.1%,
Kubota et al. [53]	0.832 (-0.329 to 1.993)		88.6%,
Leung et al. [40]	0.566 (-0.130 to 1.261)		68.6%,
Li et al. [41]	0.679 (-0.337 to 1.695)		88.1%,
Nomoto et al. [42]	0.917 (-0.153 to 1.986)		88.2%,
Shigiyama et al. [44]	0.813 (-0.262 to 1.888)		88.6%,
Suzuki et al. [25]	0.798 (-0.261 to 1.858)		88.6%,
Maruhashi et al. [23]	0.906 (-0.152 to 1.964)		88.4%,
Widlansky et al. [47]	0.899 (-0.161 to 1.960)		88.5%,
GLP-1 RA
Gurkan et al. [35]	2.435 (-1.177 to 6.047)		91.2%,
Hopkins et al. [51]	3.275 (-0.132 to 6.682)		89.2%,
Irace et al. [36]	1.141 (-1.194 to 3.476)		80.2%,
Lambadiari et al. [39]	1.902 (-1.399 to 5.203)		89.3%,
Nomoto et al. [42]	3.155 (-0.376 to 6.687)		88.1%,

DPP-4: dipeptidyl peptidase-4 inhibitors; GLP-1 RA: glucagon-like peptide-1 receptor agonists.